These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25762364)

  • 21. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
    J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
    Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
    J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canine oral melanoma.
    Bergman PJ
    Clin Tech Small Anim Pract; 2007 May; 22(2):55-60. PubMed ID: 17591290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
    Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
    J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
    Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
    Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
    Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
    Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms Enhancing the Cytotoxic Effects of Bleomycin plus Suicide or Interferon-β Gene Lipofection in Metastatic Human Melanoma Cells.
    Fondello C; Agnetti L; Glikin GC; Finocchiaro LME
    Anticancer Agents Med Chem; 2018; 18(9):1338-1348. PubMed ID: 29866016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum.
    MacEwen EG; Patnaik AK; Harvey HJ; Hayes AA; Matus R
    Cancer Invest; 1986; 4(5):397-402. PubMed ID: 3801954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
    Bergman PJ; Camps-Palau MA; McKnight JA; Leibman NF; Craft DM; Leung C; Liao J; Riviere I; Sadelain M; Hohenhaus AE; Gregor P; Houghton AN; Perales MA; Wolchok JD
    Vaccine; 2006 May; 24(21):4582-5. PubMed ID: 16188351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canine limbal melanoma: 30 cases (1992-2004). Part 2. Treatment with lamellar resection and adjunctive strontium-90beta plesiotherapy--efficacy and morbidity.
    Donaldson D; Sansom J; Adams V
    Vet Ophthalmol; 2006; 9(3):179-85. PubMed ID: 16634932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.
    Ottnod JM; Smedley RC; Walshaw R; Hauptman JG; Kiupel M; Obradovich JE
    Vet Comp Oncol; 2013 Sep; 11(3):219-29. PubMed ID: 23909996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998-2011).
    Tuohy JL; Selmic LE; Worley DR; Ehrhart NP; Withrow SJ
    J Am Vet Med Assoc; 2014 Dec; 245(11):1266-73. PubMed ID: 25406707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of lamellar resection, cryotherapy, and adjunctive grafting for the treatment of canine limbal melanoma.
    Featherstone HJ; Renwick P; Heinrich CL; Manning S
    Vet Ophthalmol; 2009; 12 Suppl 1():65-72. PubMed ID: 19891654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration.
    Klatzmann D
    Hum Gene Ther; 1996 Jan; 7(2):255-67. PubMed ID: 8788175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
    Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
    Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
    Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
    Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma.
    Westberg S; Sadeghi A; Svensson E; Segall T; Dimopoulou M; Korsgren O; Hemminki A; Loskog AS; Tötterman TH; von Euler H
    J Immunother; 2013; 36(6):350-8. PubMed ID: 23799414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.